Lucy N.
About Lucy N.
Lucy N. serves as the Associate Director of Financial Planning and Analysis at Akero Therapeutics, where she has worked since 2020. With a strong background in finance from companies like Gilead Sciences and 23andMe, she specializes in financial modeling and performance metrics.
Work at Akero Therapeutics
Currently, Lucy N. serves as the Associate Director of Financial Planning and Analysis (FP&A) at Akero Therapeutics, a position she has held since 2020. In this role, she has developed key performance indicators that enhance strategic and operational decision-making processes. Her responsibilities include overseeing financial modeling and variance analysis, utilizing her advanced Microsoft Excel skills to support the company's financial objectives.
Previous Experience in Financial Analysis
Before joining Akero Therapeutics, Lucy N. accumulated extensive experience in financial analysis at Gilead Sciences. She held multiple roles, including Senior Financial Analyst I and II, where she focused on areas such as Commercial Revenue FP&A and Royalty Revenue & Collaborations Accounting from 2013 to 2018. Additionally, she worked as a Finance Manager at 23andMe, overseeing financial operations related to therapeutics, research, and business development from 2018 to 2020.
Education and Expertise
Lucy N. holds two Bachelor of Science degrees from the University of California, San Diego, one in Management Science and another in Biology. She also completed a program at UC Berkeley Extension focused on the Drug Development Process. Her educational background supports her expertise in financial analysis, particularly in creating complex waterfall structures and developing key performance indicators.
Background in Financial Roles
Lucy N. began her career in finance at Oncomed Pharmaceuticals as a Research Associate in 2006. She later transitioned to various financial analyst roles, including Financial Analyst II in Clinical Development FP&A at Gilead Sciences. Her diverse experience across different companies and roles has equipped her with a comprehensive understanding of financial operations within the biotech and pharmaceutical industries.